XPO1 and cancer: Ataxia telangiectasia and Rad3-related (ATR) are key regulators of the DNA replication stress response and the activation of the DNA damage activation checkpoint, and previous studies have shown that XPO1 inhibition in combination with ATR inhibition may be one of the therapeutic approaches for malignant tumors.